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Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is
refractory to current regimens. The need for new treatment strategies in lymphomas has led to the investigation and evaluation of
novel agents that target cellular pathways. The mammalian target of rapamycin (mTOR) is a representative pathway that may be
implicated in lymphomagenesis. Rapamycin and especially its derivatives (temsirolimus, everolimus, and deforolimus) represent
the ﬁrst described mTOR inhibitors. These agents have shown promising results in the treatment of lymphoid malignancies. On
the other hand, new ATP-competitive mTOR inhibitors that provoke a broader inhibition of mTOR activity are in early stages of
clinical development. The purpose of this paper is to summarize the existing knowledge about mTOR inhibitors and their use in
the treatment of B-cell lymphomas. Relevant issues regarding mTOR biology in general as well as in B-cell lymphoid neoplasms
are also discussed in short.
1.Introduction
Current approaches in treating lymphoid malignancies have
focused on the development of therapeutic regimens that
selectively target dysregulated signal transduction pathways
in neoplastic cells. Among aberrantly activated signaling
cascades that are implicated in the pathogenesis of lym-
phomas is the mammalian target of rapamycin (mTOR)
pathway, which is involved in many vital cellular processes
[1]. Rapamycin and its analogs (rapalogs) comprise the
classical mTOR inhibitors. A number of completed as well
as other ongoing preclinical and clinical trials have tested
thesedrugsinlymphomas,eitherasmonotherapy orincom-
binationwithestablishedchemotherapy[1].Moreover,other
anti-mTOR molecules, such as speciﬁc active-site TOR
inhibitors (asTORi), with better pharmacological proﬁles
are candidate drugs to be tested in clinical trials against
lymphoid malignancies [2].
Herein we aim to review the results of trials with mTOR
inhibitors in B-cell lymphomas. Firstly, the mTOR signaling
network as well as possible aetiologic factors of aberrant
activationofthemTORC1signaling cascadeinB-celllymph-
oid malignancies are discussed in short.
2.mTOR Signaling Network
Rapamycin (also known as sirolimus or Rapamune, Wyeth)
is the ﬁrst described mTOR inhibitor [3]. This drug, orig-
inally developed as an antifungal agent, was soon found to
have immunosuppressive and antineoplasmatic actions [4].
Systemic eﬀorts to decipher the molecular mechanisms of
these actions led to the isolation of the mTOR protein and
the identiﬁcation of two multimolecular complexes that are
formed bymTOR,namely,themTORcomplex1(mTORC1)
and 2 (mTORC2) [4, 5]. mTOR is the mammalian ortholog
of a yeast serine-threonine kinase called target of rapamycin
(TOR) [6]. Except for mTOR itself and the proteins mLST8/
GβL [mammalian LST8 (lethal with SEC13 protein 8),
also known as G protein beta subunit-like] and DEPTOR,
which are common in both mTORC1 and mTORC2, several
diﬀerent constitutional proteins associate to form the two
mTOR complexes [7, 8]. These multipeptidic structures are2 Advances in Hematology
situated inside a signaling network, the mTOR network, cha-
racterized by many feedback loops and crosslinks among its
various components [9].
Activity of mTORC1 is regulated by multiple molecular
pathways that conduct input generated by growth factors,
hormones, cytokines, amino acids, energy, stress- and ox-
ygen-related signals [10–13]. Among these cascades are the
PI3K/Akt (Phosphoinositide 3-kinase/Akt) and Raf/MEK/
ERK (Raf/MEK/extracellular signal-regulated kinase) path-
ways, which are commonly activated in cancer and may co-
operate in malignant transformation [9, 12]. Both pathways
trigger the activity of mTORC1 through downregulation of
the inhibitory eﬀect of the TSC1-TSC2 (tuberous sclerosis
complex 1-tuberous sclerosis complex 2) complex on Rheb
(Rashomolog enriched in brain) protein [10, 12]. Aktkinase
aﬀects mTOR by way of two mechanisms. First, it lies
upstream of mTORC1 and controls its activation. Second,
Akt lies downstream of mTORC2 and depends on the latter
as well as on PDK1(pyruvate dehydrogenase kinase, isozyme
1) for full activation [7, 14].
Regulation of the two mTOR complexes bears some re-
semblance. For example, similarly to mTORC1, mTORC2
may also be activated by growth factors, hormones and ami-
no acids,and thisupregulation may bePI3Kmediated [7, 15,
16]. In contrast, the TSC1-TSC2 complex, which suppresses
mTORC1 activity, may promote mTORC2 signaling [10].
mTORC2 regulates Akt, SGK1(serum- and glucocorticoid-
induced protein kinase 1), and PKCα (protein kinase C,
alpha) phosphorylation and controls organization of actin
cytoskeleton as well as cell size, cell cycle progression,
proliferation, and survival [7, 15, 16]. The best characterized
targets of mTORC1 are the S6 kinases [S6K1 (also known
as p70S6) and S6K2] and the eukaryotic initiating factor-4e
(eIF4e) binding proteins 1 and 2 (4E-BP1 and 4E-BP2) [9–
11]. Upon activation, mTORC1 triggers vital anabolic proc-
esses such as ribosome biogenesis, cap-dependent transla
tion, uptake of nutrients including glucose and amino acids,
biosynthesis of amino acids, proteins, and lipids as well
as (adenosine triphosphate) ATP sensing. Moreover, gene
transcription, cell growth, cell cycle progression, prolifer-
ation, and survival are induced [4–7, 9, 17]. In addition,
active mTORC1 downregulates macroautophagy and other
catabolic processes such as fatty acid oxidation and protein
degradation, while, in contrast, it stimulates aerobic glycoly-
sis [4, 5, 17, 18].
Dysregulated activation of the mTORC1 pathway has
been associated with tumor biology. Aberrant mTORC1 sig-
naling disrupts homeostatic cell balance and contributes to
uncontrolled proliferation and cell growth, survival, as well
as angiogenesis and metastasis [9] .T h es a m em a l i g n a n c y -
inducing processes may be also promoted by abnormally
elevated mTORC2 signaling [16, 19–21].
3.AberrantmTORC1PathwayActivationin
B-Cell Lymphomas
Several lines of evidence indicate that aberrant activation of
the mTORC1 pathway is common in both Hodgkin (HLs)
and many types of B-cell non-Hodgkin lymphomas (NHLs)
(Table 1)[ 22–25, 27, 28, 30–33, 40–42, 46–49]. However,
the cause of this upregulation is currently poorly deﬁned.
Molecular events that aﬀect signaling pathways related to
mTORC1 complex modulation may presumably have an im-
pact on the mTORC1 pathway itself [9]. Notably, the PI3K/
Akt pathway, which is abnormally activated in many types of
B-cell lymphomas, seems to participate in mTORC1 upregu-
lation at least in a subset of these entities [22, 25, 27–29, 31–
39, 41, 43–45, 47–49]( Table 1).
Several possible mechanisms of PI3K/Akt pathway acti-
vation in mature malignant lymphoid B cells have been
described. These include (a) overexpression of membrane
receptors which may bemutationrelated,and/or stimulation
by their ligands by autocrine/paracrine secretion [23, 36–
39, 41, 50], (b) aberrant tyrosine kinase (TK) activity [51],
(c) constitution of oncogenic singalosomes [52], (d) expres-
sion of Epstein Barr virus (EBV) latent membrane protein
2A (LMP2A), and high levels of activated Ras protein
[53, 54], (e) expression of the K1 protein of Kaposi’s
sarcoma-associated herpesvirus [55], (f) overexpression of
the phosphodiesterase PDE4B gene and protein [56, 57], (g)
overexpression of the T-cell leukemia/lymphoma 1 (TCL1)
oncoprotein [58], (h) point mutations or ampliﬁcation of
the PI3K catalytic subunit alpha (PIK3CA) gene [29], and
(i) genetic or epigenetic downregulation of phosphatase and
tensin homolog (PTEN) suppressor gene [34, 35, 59, 60]. As
for the latter, a very recent study in animal models, showed
that PTEN cooperates with another negative modulator
of PI3K-mediated signaling, the Src homology 2 domain-
containing inositol phosphatase (SHIP), in order to suppress
lymphoma pathogenesis [61].
Molecular alterations that activate the PI3K/Aktpathway
could explain in part the upregulation of mTORC1 signaling
in B-cell lymphomas (Figure 1(a)).The Raf/MEK/ERKpath-
way is another candidateinducerof mTORC1activity in HLs
and NHLs (Figure 1(b)). The fact that, on one hand,
this pathway is another major upstream eﬀector of
mTORC1 and, on the other hand, it is activated in a
subset of B-cell lymphomas justiﬁes this hypothesis [24–
26, 31, 38, 39, 42, 45]( Table 1). Indeed, there is evidence
that upregulated Raf/MEK/ERK pathway may contribute
to elevated mTORC1 signaling in the setting of follicular
lymphoma (FL) and HL [25, 40, 42]. Apart from Erk, p38
is another mitogen-activated protein (MAP) kinase which
was recently suggested to induce mTORC1 activity [13]
and that may also become dysregulated in lymphomas
[25, 62–64]( Figure 1(c)). Moreover, there is evidence for a
role of the activated TK Syk in the upregulation of mTORC1
activity in FL, diffuse large B-cell lymphoma (DLBCL),
mantle cell lymphoma (MCL), and Burkitt lymphoma (BL)
cells. Notably, Syk-in-duced mTORC1 activation in FL cells
appears not to be PI3K/Akt dependent [40]. Furthermore,
Syk gene ampliﬁcation and elevated protein expression
was found in Jeko-1 MCL cell line and a few MCL tissue
samples. These alterations could potentially be related to the
activation of Syk protein and mTORC1 [65]. In addition,
phospholipase D (PLD) seems to mediate mTORC1
stimulation in two FLcell lines, while its possible implicationAdvances in Hematology 3
Table 1: Evidence of aberrant activation of mTORC1, PI3K/Akt, and Raf/MEK/ERK pathways in B-cell lymphomas.
Lymphoma Type mTORC1 activation PI3K/Akt activation MEK/ERK dysregulation Ref/s
Hodgkin Lymphoma
(HL)
Cell lines, tissue samples Cell lines, tissue samples [22]
Tissue samples [23, 24]
Tissue samples Tissue samples Tissue samples [25]
Cell lines, tissue samples [26]
Mantle Cell Lymphoma
(MCL)
Cell lines, tissue samples Cell lines, tissue samples [27, 28]
Cell lines Cell lines, tissue samples [28]
Cell lines, tissue samples [29]
Tissue samples [30]
Cell lines, Lymphoma
cells from a MCL patient
Cell lines, Lymphoma cells
from a MCL patient
Cell lines, Lymphoma cells
from a MCL patient [31]
Diﬀuse Large B-Cell
Lymphoma (DLBCL)
Tissue samples Tissue samples [32]
Cell lines, tissue samples Cell lines [33]
Tissue samples [34, 35]
Cell lines, tissue samples [36, 37]
Cell lines Cell lines [38, 39]
Follicular Lymphoma
(FL)
Cell lines, tissue samples [40]
Cell lines Cell lines [41]
Cell lines Cell lines [42]
Cell lines [43, 44]
Cell lines Cell lines [45]
Burkitt Lymphoma Cell lines [24]
Cell lines Cell lines [32, 46]
Primary Eﬀusion
Lymphoma (PEL)
Cell lines, animal model
(mice)
Cell lines, animal model
(mice) [47, 48]
Cell lines Cell lines [24]
in mTORC1 activation in other lymphomas deserves further
investigation [40]( Figure 1(d)). There are also data
suggesting the contribution of serine/threonine kinase
11 (LKB1), a tumor suppressor kinase which negatively
regulates mTORC1 activity, in lymphoma pathogenesis in
animal models. However, whether LKB1 participates in
human lymphoid malignancy induction remains uncertain
at present [66]( Figure 1(e)). On the other hand, in a study
in B-cell lymphoma cell lines mTORC1 upregulation was
shown to be dependenton nutrients butnot on other known
upstream eﬀectors [46]. As regards more proximal eﬀectors
of mTORC1, elevated levels of Rheb mRNA were found in
some aggressive NHLsthrough an unknown mechanism and
in individual cases of high increase were related to mTORC1
activation [67]. Finally, ampliﬁcation of the RPS6KB1 gene,
which encodes for p70S6/p85S6 protein, has been described
in one third of a series of DLBCLs with unknown functional
signiﬁcance in mTORC1 signaling [33].
4.mTOR Inhibitors
4.1. Rapamycin and Rapalogs. The prototype of classical
mTOR inhibitors is sirolimus [14]. The mechanism ofaction
o fs i r o l i m u si sr a t h e rc o m p l i c a t e ds i n c ei tm a yi n h i b i tm T O -
RC1orboththe two mTORcomplexesand eitherincrease or
in reduce Aktphosphorylation. These pharmaceuticaleﬀects
are dependent on dose concentration, time after adminis-
tration, and cell type [68–70]. Treatment with sirolimus may
also activate ERK. Furthermore, sirolimus diﬀerentially af-
f e c t st h em a j o rs u b s t r a t e so fm T O R C 1 ,S 6 K 1a n d4 E - B P 1 .
It seems to downregulate S6K1, in most cell types, while in
contrast inhibition of 4E-BP1 does not last long after treat-
ment and is also cell speciﬁc. Consequently, a recovery in
cap-dependent translation may be induced [17]. In malig-
nant B-cells, sirolimus may cause cell cycle arrest, reduce
proliferation, and inhibit growth in culture or delay tumor
progression in animal models [47, 49, 70–72]. In addition,
it may act similarly to amino acid deﬁciency as a positive
modulator of genes which regulate nutrient catabolism and
energy production and as a negative modulator of genes
involved in the anabolic procedures of proteins, lipids, and
nucleotides [73]. Moreover, it may potentiate the in vitro cy-
totoxicity of the chemotherapeutic agent doxorubicin, and
the histone deacetylase inhibitor LBH [22, 70]. Of interest,
sirolimus exhibits immunosuppressant properties and has
been widely administered in patients with organ transplan-
tation [3]. In addition, it may induce autophagy, both when
given as monotherapy or in combination to radiation or
dexamethasone [74–76].
Secondgeneration rapamycin derivatives(rapalogs) with
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Figure1:MolecularsignalingcascadeswhichnormallycontrolmTORC1activityandmaybecomedysregulated inB-cell lymphomasleading
to aberrant mTORC1 signaling activation. The ﬁgure also demonstrates the functions of mTORC1 and mTORC2. (a) PI3K/Akt pathway:
upon activationPI3Kmostpossiblyinduces mTORC2 complex stimulationand alsopromotes the translocationofAkt andPDK1 to the cell
membrane, where Akt becomes activated by PDK1 and mTORC2. Then, Akt activates mTORC1 by way of two mechanisms: (1) indirectly
through downregulation of the inhibitory eﬀect of the TSC1-TSC2 complex on Rheb protein and (2) directly through phosphorylation of
PRAS40(proline-rich Akt substrate of40 kilodaltons),which is a componentofthe mTORC1 complex. The tumorsuppressor phosphatases
PTEN and SHIP oppose PI3K-mediated Akt activation. (b) RAF/MEK/ERK pathway: once activated this pathwaytriggers mTORC1 activity
indirectly through inactivation of the TSC1-TSC2 complex by ERK and RSK (ribosomal S6 kinase, 90kDa). The RAF/MEK/ERK pathway
also directly activates mTORC1 through excitatory phosphorylation of raptor, a component of the mTORC1 complex, by RSK. (c) p38
is suggested to induce mTORC1 activity by acting downstream of or in parallel to Rheb. (d) PLD/phosphatidic acid (PA) pathway: upon
activation PLD hydrolyzes phosphatidylcholine (PTDC) to generate choline (CHOL) and PA. Subsequently, PA activates mTORC1 by an
unknown mechanism. (e) LKB1/AMP-dependent protein kinase (AMPK) pathway: the tumor suppressor kinase LKB1 activates AMP-
dependent protein kinase (AMPK). AMPK, in turn, inhibits mTORC1 through activation of the TSC1-TSC2 complex and direct inhibitory
phosphorylation of raptor.
molecule, facilitating their clinical use, have been developed
[77]. Currently, three of these chemical agents are available
for clinical trials: temsirolimus (CCI-779, Torisel, Wyeth
Pharmaceuticals), everolimus (RAD001, Aﬃnitor, Novar-
tis Pharmaceuticals), and ridaforolimus (AP23573, ARIAD
Pharmaceuticals, formerly deforolimus) [78]. Similarly to
rapamycin, rapalogs inhibit mTORC1, may downregulate
mTORC2, and exert either excitatory or inhibitory eﬀects
on Akt protein, both in vitro and in vivo. Moreover, these
eﬀects depend on tumor-speciﬁc characteristics, dose, and
schedule of treatment [70, 79, 80]. In B-cell lymphomas
rapalogs exhibit antiproliferative, cytostatic, and antiangio-
genic properties and may also trigger autophagy. In contrast,
they appear to have minimal or no eﬀect on survival of ma-
lignant cells [70, 81, 82]. Despite many theoretical gaps con-
cerning rapalogs’ mechanism of action, clinical trials with
these agents show promising results in lymphoid neoplasms,
apparently at the appropriate molecular background.
The pharmacokinetic and pharmacodynamic proﬁles
of rapalogs diﬀer. Temsirolimus is available in oral andAdvances in Hematology 5
Table 2: Ongoingclinical trials with rapalogs in patients with NHL.
Phase Locations Clinical trial gov. number Additional information
I/II USA NCT01076543 LenalidomideandTemsirolimusinpatientswithrelapsedorrefractoryHLorNHL
I/II USA NCT00787969 Rituximab, Cladribe, and Temsirolimus in patients with newly diagnosed MCL
I/II GERMANY NCT01078142 Temsirolimus, Bendamustine, and Rituximab for relapsed FL or MCL (BERT)
I/II USA NCT00474929 Everolimus and sorafenib for relapsed or refractory NHL, HL, or MM
I Cleveland OH NCT00671112 Everolimus plus bortezomibe for relapsed/refractory MCL and other NHL
I/II USA NCT00967044 Panobinostat (LBH589) plus Everolimus (RAD001) in patients with relapsed and
refractory Lymphoma
I/II USA NCT 101075321 EverolimusandLenalidomidein treating patients withrelapsed orrefractory NHL
or HL
I/II USA NCT00918333 PanobinostatandEverolimusin treating patientswith recurrent MM,NHL,orHL
II USA NCT00869999 Everolimus plus Rituximab for relapsed/refractory DLBCL
I/II USA NCT00704054 Deferolimus for relapsed/refractory NHL/HL
intravenous formulations. Upon administration, it is rapidly
converted to rapamycin, its primary active metabolite [83].
Phase I dose-ﬁnding studies for temsirolimus aimed to es-
tablish a maximum-tolerated dose through dose escalation,
by testing either a schedule of a daily administration of
0.75mg/m2 IV every other week with a 20% dose escala-
tion or a weekly schedule of doses ranging from 7.5mg–
220mg/m2IV [83, 84]. Maximum tolerated dose was
not established but the maximum acceptable dose was
19mg/m2/day due to grade 3 stomatitis. Although temsir-
olimus was found to be well tolerated, the most common
toxicitiesincludedneutropenia,thrombocytopenia,asthenia,
diarrhea, and stomatitis. The severity of its adverse eﬀects
was dose related. Because drug activity ceased to increase
after several dose levels, phase I studies supported the use of
a ﬂat dose for temsirolimus and the suggested dose for phase
II studies was 25, 75, or 250mg weekly.
Everolimusis orally available and typically administrated
on a daily schedule. It has been also been tested on a weekly
basis, mostly in combination regimens. Phase I studies
showed that the eﬃcacy of the drug was dose dependent
and that mTOR inhibition was more profound with daily
dosing. Inaddition, everolimuswas found to have acceptable
tolerability at the highest doses studied. The suggested dose
for phase II studies was 10mg daily or 50–70mg weekly
[85, 86].
Ridaforolimus, unlike temsirolimus, is not a prodrug
[87], and it is given typically intravenously, although oral
administration is currently under clinical testing [88]. Phase
I studies tested a daily regimen of 3–28mg and found
that mTOR inhibition increased in a less than proportional
manner. Maximum tolerated dose was 18.75mg daily due
to grade 3 mouth sores and a dose of 12mg IV daily was
proposed as suitable for phase II studies [87].
At present, numerous clinical trials are under way in
order to evaluate the above drugs as single agents or in com-
bination in aggressive and/or refractory lymphomas (Ta-
ble 2)( http://www.cancer.gov/search/ResultsClinicalTrials).
5.ClinicalTrialswithRapalogsin Lymphomas
5.1. Mantle Cell Lymphoma. Mantle Cell Lymphoma (MCL)
is an aggressive type of mature B-cell lymphoid neoplasm
with a relative frequency of 7% among NHLs. The genetic
hallmark of MCL is the translocation t(11;14)(q13;q32),
which results in overexpression of cyclin D1 [89]. It is char-
acterized by an aggressive clinical course and poor prognosis
with median survival of 3 to 5 years [90]. Although front
treatment induces a high rate of complete remission (CR),
relapse is common. Therefore, new therapies are needed
[91]. Aberrant activation of mTORC1 as well as PI3K/Akt
signaling is frequent in the MCL [27, 28, 30, 49].
Additionally, in preclinical MCL models both temsirol-
imus and everolimus showed anti-proliferative eﬀects, espe-
cially in combination with other therapeutic agents, such as
vorinostat, doxorubicin, and vortezomib [81, 82, 92, 93].
Among rapalogs, temsirolimus has been thoroughly
studied in clinical trials in MCL. In two phase II studies and
in one large randomized phase III study performed by North
Central Cancer Treatment Group (NCCTG), temsirolimus
was found to display signiﬁcant antitumor activity and clin-
ical beneﬁt as a single therapeutic agent in relapsed or re-
fractory MCL. The ﬁrst of phase II studies conducted by
Witzig et al., assessed the eﬃcacy of a250mg/week IV course
of temsirolimus monotherapy in 35 patients with relapsed or
refractory MCL that had received previous treatment. The
overall response rate (ORR) was 38%, with one complete
remission (CR) and one partial remission (PR) [94]. In the
second phase II study, Ansell et al. administered a 10-fold
lower dose of temsirolimus (25mg weekly IV) in 29 patients
with relapsed or refractory MCL and achieved a similar ORR
(41%) with one CR and ten PRs. However, the lower dose
was associated with lower rates of toxicity (50% versus 71%
grade 3 and 4% versus 11% grade 4) [95]. In both studies,
thrombocytopenia was the most common adverse eﬀect and
the most frequent cause of dose reduction. In addition, both
studies included adults (median age 70 years old) that had6 Advances in Hematology
failed previous therapies with rituximab (monoclonal anti-
CD20 antibody), cyclophosphamide, or doxorubicin [94,
95].
Based on these results, a randomized, large phase III
study was conductedto evaluatethe eﬀect of temsirolimus in
comparison to investigator’s choice therapy in 162 patients
with relapsed/refractory MCL, previously treated with ritux-
imab, alkylating agents, and anthracycline. The patients were
randomized to receive treatment with temsirolimus applied
in one of two therapeutic schemes (175mg/week for three
weeks followed by either 25mg or 75mg weekly IV) or treat-
ment with a single agent of the investigator’s choice from
approved protocols. It was shown that ORR was signiﬁ-
cantly higher in patients who received the 75mg dose of
temsirolimus compared to treatment with the investigator’s
choice agent (22% versus 2%, P = .0019). Median progres-
sion free survival (PFS) was also longer (4.8 months versus
1.9 months). Regarding patients who received 25mg tem-
sirolimus, ORR was 6% and PFS 3.4 months. Similar to the
previous trials, hematological toxicity was the most frequent
adverse eﬀect. This study demonstrated that administration
of 175/75mg temsirolimus improved ORR and PFS signifi-
cantly and showed a trend toward longer overall survival
(OS) [96]. The results of this trial led to the European ap-
proval of temsirolimus as single agent therapy for the treat-
ment of relapsed/refractory MCL [97].
More recently, Ansell et al. reported the results of the ﬁrst
phase II study that examined the eﬃcacy of temsirolimus
in combination with rituximab in patients with relapsed or
refractory MCL [98]. In this study 69 patients were treated
with temsirolimus (25mg/week) and rituximab (375mg/m2
per week) for 4 weeks during the ﬁrst cycle followed by
a single dose of rituximab every other 28-day cycle for a
total of 12 cycles. The ORR was 59% consisting of 19% CRs
and 41% PRs. The ORR was 63% for rituximab-sensitive
patients and 52% for rituximab-refractory patients. The
median time to progression (TTP) for all patients was 9.7
months (10.9months in therituximab-sensitive patients and
5.4 months in the rituximab-refractory patients). The most
common side-eﬀect was hematological toxicity which did
not diﬀer from that in the previous studies of temsirolimus
alone. Additionally, the otherm o r ef r e q u e n tg r a d e s3a n d
4 toxicities included increased serum concentrations of
cholesterol and triglycerides, hyperglycaemia, fatigue, and
dyspnoea. The frequencies of these toxicities were also
similar to that of temsirolimus as monotherapy suggesting
that rituximab can be safely combined with temsirolimus
without much increase in toxicity. The above results are
promising with much higher ORR and CR rate than in the
phase III study of temsirolimus alone without increasing
toxicity [96]. However, more randomized trials are needed
in order to establish the eﬀectiveness of the combination of
temsirolimus plus rituximab in the treatment of relapsed or
refractory MCL patients.
The eﬃcacy of everolimus in MCL was investigated in
phase II clinical trials. Witzig et al. demonstrated the antitu-
mor activity of the drug when applied as monotherapy in
relapsed/refractory NHLs. In this trial, 19 patients with
MCL, 47 patients with DLBCL and 3 patients with FL were
included. Daily dose was 10mg PO. All patients had been
heavily pretreated with a median of three previous thera-
pies and 32% of them had undergone autologous stem-
cell transplantation. In this study, ORR in patients with
MCL was 32%, lying in the middle of the 40% and 22%
that were found in the two phase II and the one phase
III trials of temsirolimus, respectively. In addition, ORR in
DLBCL patients was 30% and in FL patients 38%. Hema-
tological toxicity, mainly thrombocytopenia (38%), was
again the most frequent adverse eﬀect. Grade 3 or 4 toxicity
was observed in 68% of the patients, which was managed
easily with dose interruption or reduction [99]. On the oth-
er hand, in another phase I/II study designed to evaluate
everolimus eﬀect in 26 patients with hematological malig-
nancies including MCL, none of the 4 patients with MCL
responded to everolimus [93].
Furthermore, in the setting of MCL the activity of rid-
aforolimus has been evaluated as well. In a phase II study,
55 heavily pretreated patients with various hematological
malignancies, including 9 patients with MCL, received rid-
aforolimus as single agent (12.5mg IV once a week every 2
weeks). The most favorable response was observed in MCL
patients, with 33% ORR and three PRs. Although the num-
ber of MCL patients involved in this study was small, it
cannot be ignored that ORR achieved with ridaforolimus
is similar to that demonstrated in the two phase II studies
of single agent temsirolimus in MCL. Additionally, the fact
that 44% of MCL patients had stable disease and only two
experiencedprogressive diseaseprobablyreﬂectsapromising
antitumor activity of ridaforolimus that has to be further
investigated. Itisalsonoteworthy thatridaforolimuswaswell
tolerated. Mouth sores was the most frequent adverse eﬀect,
while thrombocytopenia was less commonly encountered
than with other rapamycin derivatives [100].
Insummary, temsirolimus isthemost extensivelystudied
mTOR inhibitor in the setting of MCL, which has been
shown to signiﬁcantly improve objective response and pro-
gression-free survival compared to investigator’s choice ther-
apy in patients with relapsed/refractory MCL in a phase
III clinical trial. The eﬀectiveness of temsirolimus in com-
bination to immunotherapy or chemotherapy has already
beenunderinvestigation. Everolimusandridaforolimushave
demonstratedpromising antitumor activityagainst MCLbut
further investigation is needed in order to evaluate their
potential eﬃcacy.
5.2. Diﬀuse Large B-Cell Lymphoma (DLBCL). Diﬀuse large
B-cell lymphoma (DLBCL)represents almost one third ofall
NHL subtypes [90]. Although standard chemotherapy reg-
imens (R-CHOP, rituximab-cyclophospamide, doxorubicin,
vincristine, and prednisone) have shown eﬀectiveness in the
treatment of DLBCL, there is still a group of patients that die
from the disease [101].
In preclinical studies, rapamycin analogue everolimus
hasbeenfoundtoinduceG1 cell-cyclearrest butnotapopto-
sis in DLBCL cell lines of the germinal centre (GC) type and
to increase the cytotoxicity of rituximab [71, 102].Advances in Hematology 7
Temsirolimus has shown promising results as a single
agent in DLBCL in a phase II study performed by University
of Chicago. The study included 89 pretreated patients with
either DLBCL, follicular lymphoma (FL), chronic lympho-
cytic leukemia (CLL), or other indolent lymphomas that
were stratiﬁed in three groups. Patients received a weekly
course of temsirolimus of 25mg. It was found that DLBCL
patients had an ORR of 28.1% with four CRs and 5 PRs
(9 patients out of 32). This result is promising, taking into
accountthatallpatientswereheavilypretreated;however,the
durability of response was short (2.4 months). Based on the
fact that nearly half of DLBCL responders had transformed
from a prior FL, authors suggest that temsirolimus might be
more active in follicle center derived lymphomas. The most
common adverse eﬀect of temsirolimus was myelosuppres-
sion, which was reversible, while other toxicities included
stomatitis and metabolic dysregulation mainly grade one or
two [103].
Everolimus has also been tested in clinical trials in
DLBCL, demonstrating response rates similar to temsirol-
imus. In a phase II study by Witzig et al. that included
77 patients with DLBCL, FL, or MCL, the ORR in DLBCL
patients was 30% (14 out of 47) [99]. However, the duration
ofresponse was longer than with temsirolimus (5.7months).
On the other hand, compared to the previous study with
temsirolimus where 4 CRs were observed, no patient among
DLBCL group who were treated with everolimus achieved
a CR. The most important adverse eﬀect in this study was
grade 3 or 4 hematologic toxicity, which appeared in 68% of
patients [103].
Deferolimus has not been investigated yet as a single
agent in the treatment of DLBCL or other NHL subtypes.
However, preliminary results show antitumor activity in
many tumor types and numerous ongoing clinical trials are
under way (Table 2)[ 87].
5.3. Follicular Lymphoma (FL). Follicular lymphoma (FL)
is the second most common type of B-NHL in the West,
accounting for 25–35% of all NHLs [90]. Patients with FL
usually have an indolent clinical course, but they might
eventually evolveto a refractory phase that can lead to death.
Activation of mTOR pathway has been demonstrated in FL
cell lines and tissue samples [40–42]. It has also been shown
that mTOR activation in FL cell lines is enhanced by Syk
independentlyofAktand also by PLD[40].However, mTOR
inhibitors have not been tested in FL cell lines or animal
models.
Both temsirolimus and everolimus have shown effect-
iveness in relapsed FL in phase II studies. In the above
mentioned study from University of Chicago, patients with
FL demonstrated an ORR of 53.8% with CR rates reaching
25.6%. Furthermore, median duration of response was 13
months, much longer than in DLBCL [103]. Similarly to
temsirolimus, everolimus has shown antitumor activity in
FL. In the previously mentioned phase II study by Witzig et
al. the reported ORR in FL was 38%, with a median duration
of response of 5.7 months. Of note, this study included
only patients with FL grade 3 [99]. These results are very
promising, but they need to be validated in further studies
that will include larger groups of patients.
5.4. Hodgkin’s Lymphoma(HL). Hodgkin’sLymphoma (HL)
represents 30% of all lymphoma cases. It is characterized
by the presence of neoplastic Hodgkin and Reed-Steinberg
cells (HRS) in a background of inﬂammatory and accessory
cells [90]. Although it has proven a highly curable disease,
there is a subset of patients that either relapse after salvage
chemotherapy or do not respond due to old age. Conse-
quently, there is still need for new therapeutic approaches.
Various studies have demonstrated activation of the
mTOR pathway in HL cell lines and primary tumors [104–
107]. The mechanism of mTOR activation in HL has not
been clariﬁed yet, but Akt is considered to play a role since
phosporylated Akt has been reported to be activated in HL
tumors [22, 108]. In HRS cells, rapamycin induces G1-S cell
cycle arrest but not apoptosis and enhances the cytotoxic
activity of doxorubicin [109]. Among rapamycin analogues,
temsirolimus has been reported to induce cell cycle arrest
followed by autophagy in HL cell lines [110]. In addition,
everolimus has been demonstrated to have antiproliferative
results in HRS cells. Furthermore, it has been shown to be
eﬀective in HL murine xenograft models [109].
Based on preclinical studies, a phase II study assessed
the eﬀectiveness of everolimus in patients with refractory/
relapsed HL. This study evaluated a total of 19 patients with
relapsed/refractory HL as part of a larger study evaluating
everolimus in more rare forms of lymphoma. Patients had
a median age of 37 years and had received a median of six
prior therapies. They were treated with a daily oral dose of
10mg and response was evaluated after two and six cycles of
therapy. The ORR was 47%, with 8 PRs and one CR. Among
those patients, 4 remained progression free at 12 years and
1 remains on therapy for more than 3 years. Of note,
74% patients experienced grade 3 or 4 toxicity. Although
hematological toxicity was the most common adverse eﬀect,
a subset of patients (11%) developed pulmonary symptoms,
such as dyspnea and cough that required dose reductions.
This high rate of toxicity should be a matter of concern
in older patients. Overall, the results of this study are
encouraging, if we take into account that responders had
stable disease on everolimus for a long period. The authors
suggest that combination of everolimus with other agents
m i g h tb ee v e nm o r ee ﬀective [110].
6.Speciﬁcand NonSpeciﬁcATP-Competitive
mTOR Inhibitors
Recently a new category of mTOR inhibitors has come
to prominence due to their ability to show a more pro-
found impact on PI3K/Akt/mTOR pathway in relation to
rapamycin and rapalogs. These drugs are small molecules
thatbindtotheATP-binding siteofmTORkinaseandinhibit
the catalytic activity of both mTOR complexes [2, 111–
122]. Two subclasses of agents are included here. The ﬁrst
subclass comprises of nonspeciﬁc ATP-competitive mTOR
inhibitors, which apart from mTORC1 and mTORC2 also8 Advances in Hematology
inhibit PI3Ks (Dual PI3K/mTOR inhibitors) [112–116]. The
second subclass consists of drugs which selectively inhibit
mTORC1 and mTORC2 without aﬀecting other kinases
[111, 117–122]. These molecules are known with diﬀerent
names such as speciﬁc active-site TOR inhibitors (asTORi)
and TOR kinase domain inhibitors (TORKinibs) [2, 115,
123].
7.Dual PI3K/mTORInhibitors
This subclass of ATP-competitive mTOR inhibitors includes
several molecules which have been applied in preclinical
models in hematologic malignancies [2, 27, 28, 49, 102, 116,
124, 125]. Two of these agents, LY294002 and wortmannin,
were initially described as PI3K inhibitors and later found to
targetmTORaswell[124].Withregard toB-celllymphomas,
both of them have been tried in MCL and FL cell lines
and were shown to downregulate Akt and/or mTOR activity
[27, 28, 40, 49]. In addition, LY294002 was shown to
decrease cyclin D1 protein levels in MCL cells, suggesting
induction of cell cycle arrest [27]. LY294002 was also applied
on DLBCL cell lines and found to trigger apoptosis in
3o u to f5c e l ll i n e si no n es t u d y .I nt h es a m es t u d y
two DLBCL cell lines excibited dephosphorylation of Akt
upon LY294002 treatment [102]. Similar were the results
regarding LY294002 eﬀect on Akt inactivation in another
study from China which also included DLBCL cell lines.
Moreover, in this study, LY294002 decreased the ratio of
S phase and of interest exhibited synergistic eﬀect with
doxorubicin on triggering apoptosis [126]. Another dual
PI3K/mTOR inhibitor, NVP-BEZ235 was recently tried in
FL cell lines and was found to inhibit cell growth and pro-
liferationduetoincreased apoptosis.Furthermore, itshowed
a synergistic activity with bortezomib against FL cell pro-
liferation [116]. Furthermore, Bhatt et al. reported that
NVP-BEZ235 suppressed proliferation in primary eﬀusion
lymphoma (PEL) cell lines and xenograft models, more efﬁ-
ciently than selective inhibitors of PI3K/Akt mTOR pathway
[48]. Although results from preclinical trials with dual
PI3K/mTOR inhibitors are preliminary and further clinical
trialsareneededtoconﬁrmthem,theseagentsseemthatmay
be potentially eﬀective in NHL treatment. Dual PI3K/mTOR
inhibitors are currently being tested in phase I trials [112].
8.Active-SiteTORInhibitors (asTORi)
All preclinical compounds in this category have been re-
ported to have similar molecular behaviour, as they have
been shown to reduce phosphorylation of both endogenous
S6 kinase and Akt [115, 117–119, 122]. Interestingly, they
a r em o r ee ﬀective mTORC1 inhibitors than rapamycin and
rapalogs, since they completely inhibit S6 kinase and 4EBP1.
Also, they trigger a more intense suppression on cap-
dependent translation, protein synthesis, cell growth and
proliferation [2, 115, 117–119, 122]. In addition, asTORi
may induce apoptosis and autophagy and in relation to
rapalogs cause a more profound decrease of lactate as well as
the angiogenic hypoxia inducible factors (HIFs) and vas-
cular endothelial growth factor (VEGF) [121, 122]. Among
asTORiagentsusedinclinicalmodels, AZD8055showssimi-
larinvitroeﬀectswithPP42,Torin-1,andKu-0063794.How-
ever, in contrast to these inhibitors AZD8055 has also been
found to inhibit tumor cell proliferation in vivo [121]. More
speciﬁcally, it induces a dose-dependent inhibition and/or
regression in human tumor xenograft models which is asso-
ciated with a dose-dependent pharmacodynamic eﬀect on
both phosphorylated S6 and phosphorylated Akt. AZD8055
is currently being evaluated in phase I studies [122]. PP42
and Ku-0063794 are two other asTORi drugs which have
shown important preclinical activity against hematological
malignancies [2]. PP42 has been found to cause death to
mouse and human Ph+ B-ALL cells, with great selectivity
to leukemia cells compared to normal bone marrow and
peripheral blood lymphocytes [120]. Moreover, PP42 has
shown marked therapeutic response in transgenic mice
that develop thymic lymphomas [127]. Regarding another
asTORi, OSI-027, it has been reported to generate antileu-
kemic eﬀects in BCR/ABL transformed cells. Based on this
ﬁnding, it is currently being evaluated in phase I studies in
solid as well as lymphoid neoplasms. Finally, INK128 has
demonstrated broad preclinical antitumor activity against
a range of solid tumor types and multiple myeloma [2].
Currently, it is also being evaluated in phase I studies. None
of these inhibitors have been tested in clinical trials in lym-
phomas yet. Further studies are currently conducted aiming
to elucidate the potential therapeutic eﬀect of asTORi-s in
neoplasms, including lymphomas.
9.Conclusions
Through the last years it has become clear that mTOR
pathway contributes to the pathogenesis of hematological
malignancies by playing a key role in the regulation of many
cell functions, such as cell proliferation, cell growth, and
angiogenesis. The development of mTOR inhibitors has
opened a new ﬁeld in the clinical arena of lymphomas.
Temsirolimus has been recently approved for the treatment
of relapsed/refractory mantle cell lymphoma. In addition,
everolimus and deferolimus have been evaluated in phase
II clinical trials that reveal their potential for the treatment
of aggressive lymphomas, justifying further evaluation with
randomized phase III trials. In addition to rapalogs, other
types of mTOR inhibitors have been currently developed,
with promising results in preclinical studies. In our opinion,
future research on the use of mTOR inhibitors in lymphoid
malignancies should aim in three basic ﬁelds: (a) identiﬁca-
tion of the whole spectrum of molecular alterations that are
related to mTOR signaling dysregulation in each lymphoma
subtype,(b)deﬁnitionofthesubsetofpatientswho are likely
to respond best to anti-mTOR treatment, and (c) design of
new clinical trials aiming to determine the eﬀectiveness of
mTOR-inhibitors in the context of established or other;
targeted or nontargeted; treatment. Undoubtedly, there is
evidence-based hope that lymphoma treatment will be
substantially improved in the next decade.Advances in Hematology 9
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